Pan Cancer T Secures Funding to Revolutionize Cancer Treatment
July 13, 2024, 9:35 pm
In a significant development in the field of cancer treatment, Pan Cancer T, a pioneering biotech startup based in Rotterdam, the Netherlands, has successfully closed a Seed Extension funding round, raising an impressive €4.25 million. This funding injection will enable the company to further advance their cutting-edge T cell therapies designed to target and treat solid cancers, particularly focusing on hard-to-treat tumors like triple negative breast cancer and melanoma.
Led by the visionary CEO Rachel Abbott, Pan Cancer T is at the forefront of developing innovative adoptive T cell therapies that have the potential to revolutionize cancer treatment. The company's approach is characterized by two key elements: the identification of unique targets for T cells that are exclusively expressed by various solid cancers, and the development of technologies that enhance the durability and effectiveness of T cells in combating these tumors.
With the support of investors such as InnovationQuarter, Van Herk Ventures, Thuja Capital, Swanbridge Capital, and Erasmus MC O&O Holdings, Pan Cancer T's total funding now stands at approximately €11 million. This financial backing will not only allow the company to complete preclinical studies for their lead TCR-T cell product, PCT1:CO-STIM, but also to progress CMC activities and advance earlier-stage pipeline projects targeting colorectal and ovarian cancers.
The significance of this funding round extends beyond the immediate financial boost for Pan Cancer T. It represents a crucial step towards bringing their innovative T cell therapies closer to clinical application, offering new hope for patients battling hard-to-treat solid tumors. CEO Rachel Abbott expressed her delight at the successful financing round, highlighting the potential of their lead product to make a tangible difference in the lives of cancer patients.
InnovationQuarter, one of the key investors in this round, emphasized the importance of supporting companies like Pan Cancer T in their quest to develop state-of-the-art cell therapies for challenging cancers. The investment not only benefits the company but also contributes to strengthening the entrepreneurial Life Sciences and Health cluster in the Province of Zuid-Holland.
Pan Cancer T's lead clinical candidate, PCT1:CO-STIM, features an IP-protected T cell receptor (TCR) that targets ROPN1, a novel tumor-restricted antigen highly expressed in a significant percentage of patients with triple negative breast cancer and melanoma. This innovative approach, combined with a proprietary TME solution that enhances T cell co-stimulation even in hostile tumor microenvironments, has shown promising results in preclinical models.
Founded in late 2020 as a spin-off from Erasmus MC, Pan Cancer T is dedicated to advancing next-generation TCR T cell therapies that have the potential to address the unmet needs of patients with a range of solid tumors. The company's commitment to developing safe and effective adoptive T cell therapies for a broad spectrum of cancers underscores their mission to make a meaningful impact in the fight against cancer.
As Pan Cancer T continues to make strides in the development of their innovative T cell therapies, the successful closure of this Seed Extension funding round marks a significant milestone in their journey towards transforming cancer treatment and offering new hope to patients facing challenging diagnoses.
Led by the visionary CEO Rachel Abbott, Pan Cancer T is at the forefront of developing innovative adoptive T cell therapies that have the potential to revolutionize cancer treatment. The company's approach is characterized by two key elements: the identification of unique targets for T cells that are exclusively expressed by various solid cancers, and the development of technologies that enhance the durability and effectiveness of T cells in combating these tumors.
With the support of investors such as InnovationQuarter, Van Herk Ventures, Thuja Capital, Swanbridge Capital, and Erasmus MC O&O Holdings, Pan Cancer T's total funding now stands at approximately €11 million. This financial backing will not only allow the company to complete preclinical studies for their lead TCR-T cell product, PCT1:CO-STIM, but also to progress CMC activities and advance earlier-stage pipeline projects targeting colorectal and ovarian cancers.
The significance of this funding round extends beyond the immediate financial boost for Pan Cancer T. It represents a crucial step towards bringing their innovative T cell therapies closer to clinical application, offering new hope for patients battling hard-to-treat solid tumors. CEO Rachel Abbott expressed her delight at the successful financing round, highlighting the potential of their lead product to make a tangible difference in the lives of cancer patients.
InnovationQuarter, one of the key investors in this round, emphasized the importance of supporting companies like Pan Cancer T in their quest to develop state-of-the-art cell therapies for challenging cancers. The investment not only benefits the company but also contributes to strengthening the entrepreneurial Life Sciences and Health cluster in the Province of Zuid-Holland.
Pan Cancer T's lead clinical candidate, PCT1:CO-STIM, features an IP-protected T cell receptor (TCR) that targets ROPN1, a novel tumor-restricted antigen highly expressed in a significant percentage of patients with triple negative breast cancer and melanoma. This innovative approach, combined with a proprietary TME solution that enhances T cell co-stimulation even in hostile tumor microenvironments, has shown promising results in preclinical models.
Founded in late 2020 as a spin-off from Erasmus MC, Pan Cancer T is dedicated to advancing next-generation TCR T cell therapies that have the potential to address the unmet needs of patients with a range of solid tumors. The company's commitment to developing safe and effective adoptive T cell therapies for a broad spectrum of cancers underscores their mission to make a meaningful impact in the fight against cancer.
As Pan Cancer T continues to make strides in the development of their innovative T cell therapies, the successful closure of this Seed Extension funding round marks a significant milestone in their journey towards transforming cancer treatment and offering new hope to patients facing challenging diagnoses.